contacts Sign In
image
author Image

UPDATE 1-BridgeBio Pharma’s heart disease drug meets main goal in late-stage study

  • Home
  • Healthcare
  • UPDATE 1-BridgeBio Pharma’s heart disease drug meets main goal in late-stage study
The company said no safety concerns were identified in patients, adding that it intends to submit marketing applications to the US Food and Drug Administration before the end of 2023, with regulatory filings in additional markets to follow in 2024.